Airway disease, obstructive https://medinfogalway.ie/index.php/ en Aminophylline Intravenous for Adults https://medinfogalway.ie/index.php/ivguides/aminophylline-intravenous-adults <div class="layout layout--onecol"> <div class="layout__region layout__region--content"> <div class="field field--name-field-tags field--type-entity-reference field--label-hidden field--items"> <div class="field--item"> </div> </div> <h2 class="field-label-above">Who can administer</h2> <p>May be administered by registered competent doctor or nurse/midwife</p> <h2 class="field-label-above">Important information</h2> <ul> <li><strong>Loading dose only given if</strong> patient not previously on oral theophylline or aminophylline (but see Further information below)</li> <li>See monitoring requirements below</li> <li>To avoid excessive dosage in <strong>obese</strong> patients, dose should be calculated on the basis of ideal body weight for height (patient is obese if actual body weight is 20% or more above ideal body weight or BMI &gt; 30) (ref 1)</li> <li>There are numerous important <strong>interactions</strong> - check latest BNF</li> <li>For Y-site compatibility <a href="#publicfiles">see below</a></li> </ul> <h2 class="field-label-above">Available preparations</h2> <p>Aminophylline 250mg per 10ml ampoule</p> <h2 class="field-label-above">Reconstitution</h2> <p>Already in solution</p> <p><strong>Draw up using a 5 micron filter needle</strong></p> <h2 class="field-label-above">Infusion fluids</h2> <p>Sodium Chloride 0.9% or Glucose 5%</p> <h2 class="field-label-above">Methods of intravenous administration</h2> <p><strong>Slow intravenous injection/Intermittent intravenous infusion (loading dose only) </strong><sup>(ref 2)</sup></p> <ul> <li>Add required dose to 100ml infusion fluid and give over <strong>at least 20 minutes</strong></li> <li>Maximum recommended rate <strong>25mg/minute</strong></li> <li><strong>Fluid restricted: can be administered undiluted, ideally via central line</strong> <sup>(ref 2)</sup></li> </ul> <p><strong>Continuous intravenous infusion (administer using an electronically controlled infusion device) </strong></p> <ul> <li>Add required dose to a suitable volume of infusion fluid e.g. 500mg to 500ml = 1mg/ml</li> <li>Administer at a rate as per 'dose' below</li> <li><strong>Fluid restricted: can be administered undiluted, ideally via central line<sup></sup></strong><sup>(ref 2)</sup></li> </ul> <h2 class="field-label-above">Dose in adults</h2> <p><strong>Usual dose </strong></p> <p><strong>Loading dose first (if appropriate)</strong></p> <ul> <li>Loading doses must <strong>NOT</strong> be given to patients already taking oral theophylline or aminophylline (but see Further information below)</li> <li>Doses should be based on <strong>ideal body weight</strong> for height - see Important information</li> <li>Give 6mg per kg (usually 250 to maximum 500mg), followed by maintenance dose.</li> <li>If patient experiences acute adverse reactions while loading dose is being given, the infusion may be stopped for 5 to 10 minutes, or administered at a slower rate <sup>(ref 3)</sup></li> </ul> <p><strong>Maintenance dose</strong></p> <ul> <li>Doses should be based on ideal body weight for height - see Further information</li> </ul> <table> <tbody> <tr> <th>Patient</th> <th>Maintenance dose FIRST 12 hours</th> <th>Maintenance dose BEYOND first 12 hours</th> </tr> <tr> <th>Healthy, NON-smokers</th> <td>0.7mg/kg/hour</td> <td>0.5mg/kg/hour - adjusted according to plasma theophylline concentrations</td> </tr> <tr> <th>ELDERLY patients</th> <td>0.6mg/kg/hour</td> <td>0.3mg/kg/hour - adjusted according to plasma theophylline concentrations</td> </tr> <tr> <th>Congestive HEART FAILURE/LIVER FAILURE</th> <td>0.5mg/kg/hour</td> <td>0.1 to 0.2mg/kg/hour - adjusted according to plasma theophylline concentrations</td> </tr> <tr> <th>Young adult SMOKERS</th> <td>1mg/kg/hour</td> <td>0.8mg/kg/hour - adjusted according to plasma theophylline concentrations</td> </tr> </tbody> </table> <h2 class="field-label-above">Monitoring</h2> <ul> <li>The half-life is approx. 8.7 hours (range 7 to 9 hours) (non-smoking, otherwise healthy asthmatic patient)</li> <li>In patients with <strong>impaired hepatic or renal function</strong>, the half-life may be prolonged</li> <li>In <strong>cigarette smokers</strong>, the half life may be reduced</li> <li>Monitor <strong>potassium - </strong>may cause hypokalaemia</li> <li>Monitor ECG, heart rate and blood pressure <sup>(ref 2)</sup></li> <li><strong>Desired levels:</strong> 10 to 20 microgram/mL<sup> (ref 3)</sup></li> <li>Adverse drug reactions may occur within the range of 10 to 20mg/L. Levels above 20mg/L are more likely to be associated with adverse effects</li> <li>Take serum level <strong>30 minutes after the loading dose</strong> has been given ('post-loading dose level')</li> <li>Start the continuous infusion once the loading dose is complete, and recheck level after 12 hours- (to determine if levels are increasing or decreasing from post-loading dose level)</li> <li>Adjust infusion rates according to the following table <sub>(ref 4)</sub></li> </ul> <table> <tbody> <tr> <th>Serum theophylline concentration (micrograms per ml)</th> <th>Dosage adjustment (ADULT PATIENTS)</th> </tr> <tr> <th>less than 9.9</th> <td> <p>Increase infusion rate by 25% if symptoms <strong>are not controlled</strong> and current dosage is tolerated.</p> <p>Recheck levels after 24 hours</p> </td> </tr> <tr> <th>10 to 14.9</th> <td> <p>Maintain infusion rate if symptoms are controlled and current dosage is tolerated.</p> <p>If symptoms are not controlled and dosage is tolerated, consider addition of additional agents</p> <p>Recheck levels after 24 hours</p> </td> </tr> <tr> <th>15 to 19.9</th> <td> <p>Some references suggest a 10% reduction in infusion rate to provide greater margin of safety even if current dosage is tolerated.</p> <p>Alternatively, maintain infusion rate if symptoms are controlled and current dosage is tolerated.</p> <p>Recheck levels after 24 hours</p> </td> </tr> <tr> <th>20 to 24.9</th> <td> <p>Decrease infusion rate by 25% even if no adverse reactions are present.</p> <p>Recheck levels after 24 hours</p> </td> </tr> <tr> <th>25 to 30</th> <td> <p>Stop infusion for 24 hours.</p> <p>If symptomatic consider whether treatment for overdose is indicated</p> <p>Subsequently decrease infusion rate by at least 25% even if no adverse effects are present</p> <p>Recheck levels after 24 hours</p> </td> </tr> <tr> <th>Greater than 30</th> <td> <p>Stop infusion and treat overdose if indicated</p> <p>If therapy is resumed, decrease subsequent infusion rate by at least 50%.</p> <p>Recheck levels after 24 hours</p> </td> </tr> <tr> <th colspan="2">Dose adjustment and/or serum theophylline levels are indicated whenever adverse effects are present, or interacting drugs are commenced or discontinued.</th> </tr> </tbody> </table> <h2 class="field-label-above">Further information</h2> <ul> <li><strong>Loading doses: </strong>Ideally the loading dose would be deferred until serum theophylline levels are known. If this is not possible, and if the clinical situation requires that the drug be given, a dose of 3.1mg/kg of aminophylline may be considered, on the basis that it is likely to increase the serum theophylline concentration by about 5 mcg/L when administered as a loading dose</li> <li>Patients on intravenous aminophylline need careful monitoring and nursing attention</li> <li>Rapid administration has been associated with <strong>acute hypotension, arrhythmias and convulsions </strong></li> <li>Concurrent use of other xanthine derivatives are contraindicated due to the risk of toxicity</li> <li>Each 0.5mg/kg aminophylline administered as a loading dose gives rise to a 1mcg/ml increase in serum concentrations of theophylline</li> <li>Patient is obese if actual body weight is 20% or more above ideal body weight or BMI &gt; 30 <sup>(ref 3)</sup> <p><strong>Ideal body weight (IBW) calculations</strong></p> </li> <li> <p><strong>Male </strong> 50kg + (2.3 x inches over 5 feet) <strong>or </strong>50kg + (0.9 x cm over 152 cm)</p> </li> <li> <p><strong>Female </strong>45.5kg + (2.3 x inches over 5 feet) <strong>or </strong>45.5kg + (0.9 x cm over 152 cm)</p> </li> </ul> <h2 class="field-label-above">Storage</h2> <p>Store below 25<sup>0</sup>C</p> <h2 class="field-label-above">References</h2> <p>1: Sanford guide to antimicrobial therapy 2011 (information on obesity extrapolated from data on antimicrobials)</p> <p>2: Injectable medicines guide Medusa, accessed online 20/01/22</p> <p>3: SPC Mercury pharmaceuticals October 2020</p> <p>4: Uptodate: accessed 20/01/22</p> <p>5: UK SPC ADVANZ pharmaceuticals October 2020</p> <h2 class="field-label-above">Therapeutic classification</h2> <p>Bronchodilator - Theophylline</p> <div class="field field--name-field-categories field--type-entity-reference field--label-above"> <div class="field--label">BNF</div> <div class="field--items"> <div class="field--item"><a href="/index.php/taxonomy/term/71" hreflang="en">Airway disease, obstructive</a></div> </div> </div> <div class="field field--name-field-type field--type-entity-reference field--label-above"> <div class="field--label">IV Guide Type</div> <div class="field--items"> <div class="field--item"><a href="/index.php/taxonomy/term/136" hreflang="en">Respiratory</a></div> </div> </div> </div> </div> Fri, 15 Feb 2008 08:36:04 +0000 admin 2749 at https://medinfogalway.ie